BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23288637)

  • 1. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype.
    Yee NS
    Adv Exp Med Biol; 2013; 779():91-143. PubMed ID: 23288637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
    Matsuoka T; Yashiro M
    World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma.
    Yee NS; Kazi AA; Yee RK
    Curr Clin Pharmacol; 2015; 10(4):256-66. PubMed ID: 26548903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New targeted therapies in pancreatic cancer.
    Seicean A; Petrusel L; Seicean R
    World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
    Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Novel Treatment Strategy for Pancreatic Cancer Based on Gene Profiles].
    Hayashi H; Nishihara H
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1326-1331. PubMed ID: 27899773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma].
    Ormanns S
    Pathologe; 2018 Dec; 39(Suppl 2):221-224. PubMed ID: 30361776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?
    O'Hayer KM; Brody JR
    Discov Med; 2016 Feb; 21(114):117-23. PubMed ID: 27011047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pancreatic cancer stem cell].
    Hamada S; Masamune A; Shimosegawa T
    Nihon Rinsho; 2015 May; 73(5):844-9. PubMed ID: 25985641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies.
    Hussain I; Rashid MU; Sarvepalli D; Rahman AU; Ullah W; Badar H; Jehanzeb S; Khan AK; Khan MT; Muzammil M; Ahmad S
    Crit Rev Oncog; 2019; 24(2):157-177. PubMed ID: 31679211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis of cancer and the development of targeted therapy.
    Riley LB; Desai DC
    Surg Clin North Am; 2009 Feb; 89(1):1-15, vii. PubMed ID: 19186227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathobiology of pancreatic cancer: implications on therapy.
    Regel I; Hausmann S; Benitz S; Esposito I; Kleeff J
    Expert Rev Anticancer Ther; 2016; 16(2):219-27. PubMed ID: 26652651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
    Wright GP; Chesla DW; Chung MH
    Am J Surg; 2016 Mar; 211(3):506-11. PubMed ID: 26754455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer stem cells: new insight into a stubborn disease.
    Zhan HX; Xu JW; Wu D; Zhang TP; Hu SY
    Cancer Lett; 2015 Feb; 357(2):429-37. PubMed ID: 25499079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Implications of Wingless/int1 (WNT) Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
    Nakamoto M; Hisaoka M
    J UOEH; 2016 Mar; 38(1):1-8. PubMed ID: 26972939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.
    Jazieh KA; Foote MB; Diaz LA
    Semin Radiat Oncol; 2014 Apr; 24(2):67-76. PubMed ID: 24635863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.
    Fang Y; Yao Q; Chen Z; Xiang J; William FE; Gibbs RA; Chen C
    Med Sci Monit; 2013 Oct; 19():916-26. PubMed ID: 24172537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.